v3.26.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Current assets:    
Cash $ 5,106,872 $ 1,038,952
Prepaid insurance 26,682 20,898
Other prepaid expenses 44,825 85,653
Total current assets 5,178,379 1,145,503
LiGHT proton therapy system equipment 6,582,560
Right-of-use lease assets 972,682
Total assets 12,733,621 1,145,503
Current liabilities:    
Accounts payable and accrued expenses, including $125,959 and $27,500 to related parties at December 31, 2025 and December 31, 2024, respectively 436,482 83,206
Research and development contract liabilities 232,138 235,078
Operating lease obligations, current 595,418
Series B Convertible Preferred Stock 8% cumulative dividend payable 69,073
Total current liabilities 1,333,111 318,284
Operating lease obligations, long-term 438,959
Total liabilities 1,772,070 318,284
Commitments and Contingencies
Stockholders’ Equity:    
Common stock, $0.0001 par value authorized – 100,000,000 shares; issued and outstanding – 8,790,102 and 2,249,290 shares at December 31, 2025 and 2024, respectively 879 225
Additional paid-in capital 66,008,824 49,394,687
Accumulated deficit (58,077,213) (52,067,693)
Total Lixte Biotechnology stockholders’ equity 9,664,059 827,219
Non-controlling interest 1,297,492
Total stockholders’ equity 10,961,551 827,219
Total liabilities and stockholders’ equity 12,733,621 1,145,503
Series A Convertible Preferred Stock [Member]    
Stockholders’ Equity:    
Preferred Stock, value 3,500,000
Series B Convertible Preferred Stock [Member]    
Stockholders’ Equity:    
Preferred Stock, value $ 1,731,569

Source

HTML PDF
ZIP